|
|
||||||||





* Cardiovascular Research Center, Departments of
Molecular Physiology and Biological Physics and
Medicine, University of Virginia, Charlottesville, VA 22908; and
Adenosine Therapeutics, LLC, Charlottesville, VA 22911
Activation of the A2A adenosine receptor (A2AR) during reperfusion of various tissues has been found to markedly reduce ischemia-reperfusion injury. In this study, we used bone marrow transplantation (BMT) to create chimeric mice that either selectively lack or selectively express the A2AR on bone marrow-derived cells. Bolus i.p. injection of the selective A2A agonist, 4-{3-[6-amino-9-(5-cyclopropylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid methyl ester (ATL313; 3 µg/kg), at the time of reperfusion protects wild-type (wt) mice from liver ischemia-reperfusion injury. ATL313 also protects wt/wt (donor/recipient BMT mouse chimera) and wt/knockout chimera but produces modest protection of knockout/wt chimera as assessed by alanine aminotransferase activity, induction of cytokine transcripts (RANTES, IFN-
-inducible protein-10, IL-1
, IL-1-
, IL-1R
, IL-18, IL-6, and IFN-
), or histological criteria. ATL313, which is highly selective for the A2AR, produces more liver protection of chimeric BMT mice than 4-{3-[6-amino-9-(5-ethylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-cyclohexanecarboxylic acid methyl ester, which is rapidly metabolized in mice to produce 4-{3-[6-amino-9-(5-ethylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-cyclohexanecarboxylic acid, which has similar affinity for the A2AR and the proinflammatory A3 adenosine receptor. GFP chimera mice were created to show that vascular endothelial cells in the injured liver do not account for liver protection because they are not derived by transdifferentiation of bone marrow precursors. The data suggest that activation of the A2AR on bone marrow-derived cells is primarily responsible for protecting the liver from reperfusion injury.
This article has been cited by other articles:
![]() |
T. H. Rork, K. L. Wallace, D. P. Kennedy, M. A. Marshall, A. R. Lankford, and J. Linden Adenosine A2A receptor activation reduces infarct size in the isolated, perfused mouse heart by inhibiting resident cardiac mast cell degranulation Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H1825 - H1833. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Hart, C. Much, D. Kohler, J. Schittenhelm, I. C. Gorzolla, G. L. Stahl, and H. K. Eltzschig Use of a hanging-weight system for liver ischemic preconditioning in mice Am J Physiol Gastrointest Liver Physiol, June 1, 2008; 294(6): G1431 - G1440. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xu, K. Ravid, and B. D. Smith Major Histocompatibility Class II Transactivator Expression in Smooth Muscle Cells from A2b Adenosine Receptor Knock-out Mice: CROSS-TALK BETWEEN THE ADENOSINE AND INTERFERON-{gamma} SIGNALING J. Biol. Chem., May 23, 2008; 283(21): 14213 - 14220. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Hasko and P. Pacher A2A receptors in inflammation and injury: lessons learned from transgenic animals J. Leukoc. Biol., March 1, 2008; 83(3): 447 - 455. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Garcia, L. D. Truong, P. Li, P. Zhang, J. Du, J.-F. Chen, and L. Feng Adenosine A2A receptor activation and macrophage-mediated experimental glomerulonephritis FASEB J, February 1, 2008; 22(2): 445 - 454. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. L. Kolachala, R. Bajaj, M. Chalasani, and S. V. Sitaraman Purinergic receptors in gastrointestinal inflammation Am J Physiol Gastrointest Liver Physiol, February 1, 2008; 294(2): G401 - G410. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Gazoni, V. E. Laubach, D. P. Mulloy, A. Bellizzi, E. B. Unger, J. Linden, P. I. Ellman, T. C. Lisle, and I. L. Kron Additive protection against lung ischemia-reperfusion injury by adenosine A2A receptor activation before procurement and during reperfusion J. Thorac. Cardiovasc. Surg., January 1, 2008; 135(1): 156 - 165. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Caldwell, J. Tschoep, and A. B. Lentsch Lymphocyte function during hepatic ischemia/reperfusion injury J. Leukoc. Biol., September 1, 2007; 82(3): 457 - 464. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Reutershan, R. E. Cagnina, D. Chang, J. Linden, and K. Ley Therapeutic Anti-Inflammatory Effects of Myeloid Cell Adenosine Receptor A2a Stimulation in Lipopolysaccharide-Induced Lung Injury J. Immunol., July 15, 2007; 179(2): 1254 - 1263. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Lappas, Y.-J. Day, M. A. Marshall, V. H. Engelhard, and J. Linden Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation J. Exp. Med., November 27, 2006; 203(12): 2639 - 2648. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Awad, L. Huang, H. Ye, E. T. A. Duong, W. K. Bolton, J. Linden, and M. D. Okusa Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy Am J Physiol Renal Physiol, April 1, 2006; 290(4): F828 - F837. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-C. Toufektsian, Z. Yang, K. M. Prasad, L. Overbergh, S. I. Ramos, C. Mathieu, J. Linden, and B. A. French Stimulation of A2A-adenosine receptors after myocardial infarction suppresses inflammatory activation and attenuates contractile dysfunction in the remote left ventricle Am J Physiol Heart Circ Physiol, April 1, 2006; 290(4): H1410 - H1418. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |